

Regimen Reference Order – pegylated liposomal doxorubicin desensitization

pegylated liposomal doxorubicin desensitization protocol is prescribed in combination with a pegylated liposomal doxorubicin-based protocol

ARIA: SUPP - [doxo (peg-lipo) (desens) 30]

SUPP - [doxo (peg-lipo) (desens) 40]

SUPP - [doxo (peg-lipo) (desens) 50]

Planned Course: Refer to prescribed pegylated liposomal doxorubicin-based protocol

Indication for Use: Eligible patients with previous hypersensitivity reactions to pegylated liposomal doxorubicin

Alert: Desensitization protocol

pegylated liposomal doxorubicin:

- *pegylated liposomal doxorubicin is prepared in 3 separate bags with a total volume of 250 mL in BAG 1, 63 mL in BAG 2 and 250 mL in BAG 3*
- *pegylated liposomal doxorubicin must be the first chemotherapy agent administered when given in combination with another chemotherapy agent*
- *IV tubing is primed with pegylated liposomal doxorubicin (Cytotoxic)*
- *pegylated liposomal doxorubicin is administered slowly following specified rate increases. pegylated liposomal doxorubicin infusion takes approximately 5.75 hours to complete*

CVAD: At Provider’s Discretion

Blood work requirements:

- ❖ *Refer to prescribed pegylated liposomal doxorubicin-based protocol*

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements		
Drug	Dose	CCMB Administration Guideline
<i>Refer to prescribed pegylated liposomal doxorubicin-based protocol</i>		

Treatment Regimen – pegylated liposomal doxorubicin desensitization		
Establish primary solution 500 mL of: D5W		
Drug	Dose	CCMB Administration Guideline
Antiemetics		Refer to prescribed pegylated liposomal doxorubicin-based protocol
montelukast	10 mg	Orally 1 hour prior to pegylated liposomal doxorubicin

cetirizine	20 mg	Orally 1 hour prior to pegylated liposomal doxorubicin
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes 1 hour prior to pegylated liposomal doxorubicin <i>*Nursing Alert: pegylated liposomal doxorubicin starts 1 hour after completion of dexamethasone infusion</i>
Wait 1 hour after completion of IV pre-medication(s) before starting pegylated liposomal doxorubicin		
doxorubicin, peg-liposomal (pegylated liposomal doxorubicin)	1/100 th (1%) of dose (BAG 1)	IV in D5W 250 mL following the administration rates below: Step 1: 2 mL/hour for 15 minutes, then Step 2: 5 mL/hour for 15 minutes, then Step 3: 10 mL/hour for 15 minutes, then Step 4: 20 mL/hour for 15 minutes Once step 4 is complete, discard remainder of bag and proceed immediately to BAG 2 <i>*Alert: Pharmacy to ensure final volume in bag = 250 mL</i> <i>*Alert: pegylated liposomal doxorubicin must be the first chemotherapy agent administered when given in combination with another chemotherapy agent</i> <i>*Nursing Alert: IV tubing is primed with pegylated liposomal doxorubicin</i>
	2.5% of dose (BAG 2)	IV in D5W 63 mL following the administration rates below: Step 5: 5 mL/hour for 15 minutes, then Step 6: 10 mL/hour for 15 minutes, then Step 7: 20 mL/hour for 15 minutes, then Step 8: 40 mL/hour for 15 minutes Once step 8 is complete, discard remainder of bag and proceed immediately to BAG 3 <i>*Alert: Pharmacy to ensure final volume in bag = 63 mL</i> <i>*Nursing Alert: IV tubing is primed with pegylated liposomal doxorubicin</i>
	96.5% of dose (BAG 3)	IV in D5W 250 mL following the administration rates below: Step 9: 10 mL/hour for 15 minutes, then Step 10: 20 mL/hour for 15 minutes, then Step 11: 40 mL/hour for 15 minutes, then Step 12: 75 mL/hour until infusion is complete <i>*Alert: Pharmacy to ensure final volume in bag = 250 mL</i> <i>*Nursing Alert: IV tubing is primed with pegylated liposomal doxorubicin</i>

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required after pegylated liposomal doxorubicin administration. Patient can be discharged from treatment room if stable whether they had a reaction or not
- Refer to the prescribed pegylated liposomal doxorubicin-based protocol for additional monitoring

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
<i>Refer to prescribed pegylated liposomal doxorubicin-based protocol</i>		

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity occur after discharge
- Refer to the prescribed pegylated liposomal doxorubicin-based protocol for additional instructions
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Oncologist must write first prescription of pegylated liposomal doxorubicin desensitization protocol
- Once the patient requires pegylated liposomal doxorubicin desensitization protocol, all subsequent pegylated liposomal doxorubicin doses must be given using pegylated liposomal doxorubicin desensitization protocol
- Refer to the prescribed pegylated liposomal doxorubicin-based protocol for additional pegylated liposomal doxorubicin information
- Support protocols are available under **doxo (peg-lipo) 30**, **doxo (peg-lipo) 40** and **doxo (peg-lipo) 50** in the “Desensitization” folder
- Due to the duration of treatment, administration site restrictions may be in place for pegylated liposomal doxorubicin desensitization